Metastatic pancreatic cancer – pipeline review, h2 2012

  • 222 views
Uploaded on

2012 || Oncology || Metastatic Pancreatic Cancer – Pipeline Review, H2 2012 || Aarkstore.com

2012 || Oncology || Metastatic Pancreatic Cancer – Pipeline Review, H2 2012 || Aarkstore.com

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
222
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
2
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Aarkstore.com announces, The Latest market research report is available inits vast collection:Metastatic Pancreatic Cancer – Pipeline Review, H2 2012http://www.aarkstore.com/reports/Metastatic-Pancreatic-Cancer-Pipeline-Review-H2-2012-220618.htmlRSS link of Global Markets Directhttp://www.aarkstore.com/feeds/Global-Markets-Direct.xmlSummaryGlobal Markets Direct’s, Metastatic Pancreatic Cancer - Pipeline Review, H2 2012,provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. Thisreport provides information on the therapeutic development for MetastaticPancreatic Cancer, complete with latest updates, and special features on late-stageand discontinued projects. It also reviews key players involved in the therapeuticdevelopment for Metastatic Pancreatic Cancer. Metastatic Pancreatic Cancer -Pipeline Review, H2 2012 is built using data and information sourced from GlobalMarkets Direct’s proprietary databases, Company/University websites, SEC filings,investor presentations and featured press releases from company/university sitesand industry-specific third party sources, put together by Global Markets Direct’steam.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Metastatic Pancreatic Cancer.- A review of the Metastatic Pancreatic Cancer products under development bycompanies and universities/research institutes based on information derived fromcompany and industry-specific sources.- Coverage of products based on various stages of development ranging from
  • 2. discovery till registration stages.- A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.Table of contents:List of Tables 7List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Metastatic Pancreatic Cancer Overview 11Therapeutics Development 12An Overview of Pipeline Products for Metastatic Pancreatic Cancer 12Metastatic Pancreatic Cancer Therapeutics under Development by Companies 14Metastatic Pancreatic Cancer Therapeutics under Investigation byUniversities/Institutes 18Late Stage Products 24Comparative Analysis 24Mid Clinical Stage Products 25Comparative Analysis 25Early Clinical Stage Products 26Comparative Analysis 26Metastatic Pancreatic Cancer Therapeutics – Products under Development byCompanies 27Metastatic Pancreatic Cancer Therapeutics – Products under Investigation byUniversities/Institutes 29Companies Involved in Metastatic Pancreatic Cancer Therapeutics Development 37F. Hoffmann-La Roche Ltd. 37Amgen Inc. 38Eli Lilly and Company 39GlaxoSmithKline plc 40Gilead Sciences, Inc. 41Daiichi Sankyo Company, Ltd 42Infinity Pharmaceuticals, Inc. 43YM BioSciences Inc. 44FibroGen, Inc. 45
  • 3. Novartis AG 46Astellas Pharma Inc. 47Chugai Pharmaceutical Co. Ltd 48Aduro BioTech 49List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H22012&PubId=&pagenum=1Brain Tumor – Pipeline Review, H2 2012Colon Cancer – Pipeline Review, H2 2012Hodgkin Lymphoma – Pipeline Review, H2 2012Substance (Drug) Abuse – Pipeline Review, H2 2012Metastatic Pancreatic Cancer – Pipeline Review, H2 2012Neuro Endocrine (Carcinoid) Carcinoma – Pipeline Review, H2 2012B-Cell Leukemia – Pipeline Review, H2 2012Malignant Neoplasms – Pipeline Review, H2 2012
  • 4. Recurrent Malignant Glioma – Pipeline Review, H2 2012Endobronchial Cancer – Pipeline Review, H2 2012Leiomyosarcoma – Pipeline Review, H2 2012Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H2 2012Esophageal Tumor – Pipeline Review, H2 2012Malignant Pleural Mesothelioma – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcarehttp://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: enquiry@aarkstore.com